pembrolizumab + carboplatin + patritumab deruxtecan

A combination regimen consisting of **pembrolizumab** (a monoclonal antibody targeting PD-1 and immune checkpoint inhibitor), **carboplatin** (a platinum-based DNA cross-linking chemotherapeutic), and **patritumab deruxtecan** (an antibody-drug conjugate targeting HER3, combining a fully human anti-HER3 antibody with a topoisomerase I inhibitor payload via a cleavable linker). This regimen aims to combine immunotherapy, cytotoxic chemotherapy, and targeted antibody-drug conjugate therapy. It is under clinical investigation primarily for the neoadjuvant treatment of triple-negative breast cancer and hormone receptor low positive/HER2-negative breast cancer, with the goal to increase pathological complete response rates and improve outcomes before surgery[1][3].